Search
Search titles only
By:
Search titles only
By:
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Forums
New posts
All threads
Latest threads
New posts
Trending threads
Trending
Search forums
What's new
New posts
New ads
New profile posts
Latest activity
Free Ads
Latest reviews
Search ads
Members
Current visitors
New profile posts
Search profile posts
Contact us
Latest ads
AI Chat Bot for Websites
sajith.xp.pk
Updated:
Yesterday at 1:17 PM
Puffin Rock Characters Plush Toy Set
anil1961
Updated:
Nov 7, 2026
Toyota Vitz scp10 For Sale
Lakmal Bandara
Updated:
Nov 4, 2026
Kandy
Welcome all my all new pet shop Bark.lk
dilumrane
Updated:
Nov 2, 2026
Windows RDP Only Rs.500 a month
Blogerwiki
Updated:
Nov 1, 2026
Electronics
Vehicles
Property
Search
Reply to thread
Forums
ElaKiri.com
News and Updates
Sinopharm - Budapest Study
Get the App
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="udithshan" data-source="post: 26799247" data-attributes="member: 363321"><p>Budapest, Hungary (AP) -- A new study suggests that a Sinopharm vaccine offers poor protection from COVID-19 among the elderly, raising questions for dozens of countries that have given the Chinese company’s shots to their most vulnerable populations.</p><p></p><p>A survey of blood samples taken from 450 people in Hungary at least two weeks after their second Sinopharm dose found that 90% under 50 years old developed protective antibodies. But the percentage declined with age, and 50% of those over 80 had none.</p><p></p><p></p><p>The study by two Hungarian researchers was posted online this week but not yet reviewed by other scientists. Three outside experts said they had no problems with the methodology of the study of the vaccine developed by Sinopharm’s Beijing Institute of Biological Products.</p><p></p><p>“This is very, very worrying that these people, who are high-risk, have a poor antibody response,” said Jin Dong-yan, a Hong Kong University virologist who was not affiliated with the study</p><p></p><p>Source - <a href="https://www.bloomberg.com/news/articles/2021-07-23/study-chinese-covid-shot-may-offer-elderly-poor-protection" target="_blank">Bloomberg</a></p></blockquote><p></p>
[QUOTE="udithshan, post: 26799247, member: 363321"] Budapest, Hungary (AP) -- A new study suggests that a Sinopharm vaccine offers poor protection from COVID-19 among the elderly, raising questions for dozens of countries that have given the Chinese company’s shots to their most vulnerable populations. A survey of blood samples taken from 450 people in Hungary at least two weeks after their second Sinopharm dose found that 90% under 50 years old developed protective antibodies. But the percentage declined with age, and 50% of those over 80 had none. The study by two Hungarian researchers was posted online this week but not yet reviewed by other scientists. Three outside experts said they had no problems with the methodology of the study of the vaccine developed by Sinopharm’s Beijing Institute of Biological Products. “This is very, very worrying that these people, who are high-risk, have a poor antibody response,” said Jin Dong-yan, a Hong Kong University virologist who was not affiliated with the study Source - [URL='https://www.bloomberg.com/news/articles/2021-07-23/study-chinese-covid-shot-may-offer-elderly-poor-protection']Bloomberg[/URL] [/QUOTE]
Insert quotes…
Verification
Asuwa dahayen wadi kalama keeyada?
Post reply
Top
Bottom